Government-Owned Inventions; Availability for Licensing, 1647-1648 [2014-00123]
Download as PDF
<![CDATA[
PMANGRUM on DSK3VPTVN1PROD with NOTICES
Federal Register / Vol. 79, No. 6 / Thursday, January 9, 2014 / Notices
US–01); PCT Patent Application No.
PCT/US2006/040134, entitled ‘‘Rabies
Virus Compositions and Methods’’, filed
October 13, 2006, (E–326–2013/0–PCT–
02); and Chinese Patent Application No.
200680038314.4, entitled ‘‘Rabies Virus
Compositions and Methods’’, filed
October 13, 2006 (HHS Ref. No. E–326–
2013/0–CN–06). The patent rights in
these inventions have been assigned to
the Government of the United States of
America. The prospective exclusive
license territory is China, and the field
of use may be limited to ‘‘Rabies
vaccines based on the ERAg3m virus
strain for veterinary use only.’’
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before
February 10, 2014 will be considered.
ADDRESSES: Requests for copies of the
patent application(s), inquiries, and
comments relating to the contemplated
exclusive license should be directed to:
Whitney Blair, J.D., M.P.H., Licensing
and Patenting Manager, Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
Telephone: (301) 435–4937; Facsimile:
(301) 402–0220; Email: whitney.blair@
nih.gov.
SUPPLEMENTARY INFORMATION: This
license specifically concerns a highly
attenuated rabies virus, ERAg3m, with a
mutation in the glycoprotein (G) gene
and a switch of the G gene with the
matrix protein gene in the viral genome.
After a one-dose intramuscular
vaccination, the ERAg3m virus
protected 100% of mice and hamsters
from lethal challenge. ERAg3m also may
offer better protection than traditional
inactivated vaccinations, as
demonstrated in co-infection studies.
This technology is capable of being
developed into a one-dose rabies
vaccine for human or veterinary use.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR part 404. The
prospective exclusive license may be
granted unless within thirty (30) days
from the date of the published notice,
the NIH receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
VerDate Mar<15>2010
14:08 Jan 08, 2014
Jkt 232001
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: January 2, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2014–00126 Filed 1–8–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUMMARY:
New Compounds for Treating or
Preventing Obesity
Description of Technology: Available
for licensing are new compounds
developed for the treatment or
prevention of obesity. The compounds
act to block the absorption of dietary
fats in the gut by interfering with
signaling through the farnesoid X
receptor. There is correlative evidence
that inhibition of the farnesoid X
receptor can reduce obesity resulting
from high fat-based diets. While many
farnesoid X receptor agonists are
known, until now there have been no
known therapeutic agents that can
inhibit this receptor.
Also available for licensing are
methods of synthesizing the compounds
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
1647
and methods of using the compounds to
treat or prevent obesity.
Potential Commercial Applications:
• Pharmaceutical treatments for
obesity.
• Pharmaceutical agents to reduce
weight gain.
Competitive Advantages:
• There are no known therapeutic
agents to inhibit the farnesoid X
receptor; thus, agents developed from
the present technology could be first-tomarket.
• Compounds stay in the intestine
and are not toxic.
Development Stage:
• Early-stage.
• In vitro data available.
• In vivo data available (animal).
Inventors: Frank Gonzalez, Fei Li,
Changtao Jiang, James Mitchell (all of
NCI).
Intellectual Property: HHS Reference
No. E–508–2013/0—US Provisional
Application No. 61/861,109 filed 01
August 2013.
Licensing Contact: Patrick McCue,
Ph.D.; 301–435–5560; mccuepat@
mail.nih.gov.
Chimeric Antigen Receptors to CD276
(B7–H3) for Treatment of Cancer
Description of Technology: Chimeric
antigen receptors (CARs) are hybrid
proteins consisting of an antibody
binding fragment fused to protein
signaling domains. When CARs are
expressed in T-cells, the T-cells become
cytotoxic towards cells expressing the
proteins that the CAR recognizes. By
developing a CAR that is specific for a
cell surface protein that is selectively
expressed on diseased cells, it is
possible to selectively target those cells
for destruction, thereby treating the
disease.
Solid tumors are typically treated
with a non-specific approach of surgical
resection, followed by chemotherapy or
radiation therapy. Unfortunately, such
an approach is traumatic for the patient,
and leads to numerous side-effects. This
suggests that a more specific approach
to treating solid tumors is needed.
CD276 (B7–H3) is a tumor-associated
antigen that is expressed on several
solid tumors, making it a promising
therapeutic target. This technology
concerns the generation of three highaffinity CARs (CD276.1, CD276.6 and
CD276.17) that target CD276. These
CARs can potentially be used in the
treatment of cancers associated with
CD276 expression.
Potential Commercial Applications:
• Treatment of diseases associated
with increased or preferential
expression of CD276.
• Specific diseases include
neuroblastoma, Ewing’s sarcoma,
E:\FR\FM\09JAN1.SGM
09JAN1
1648
Federal Register / Vol. 79, No. 6 / Thursday, January 9, 2014 / Notices
rhabdomyosarcoma, and prostate,
ovarian, colorectal, and lung cancers.
Competitive Advantages:
• High affinity of the CARs increases
the likelihood of successful targeting.
• Targeted therapy decreases nonspecific killing of healthy, essential
cells, resulting in fewer non-specific
side-effects and healthier patients.
Development Stage:
• Early-stage.
• In vitro data available.
Inventors: Rimas J. Orentas, et al.
(NCI).
Intellectual Property: HHS Reference
No. E–104–2013/0–US–01—US
Provisional Patent Application No. 61/
805,001 filed 25 March 2013.
Related Technologies:
• HHS Reference No. E–291–2012/
0—International Patent Application No.
PCT/US2013/060332 filed 18 September
2013; ‘‘M971 Chimeric Antigen
Receptors,’’ Orentas R, et al.
• HHS Reference No. E–007–2014/
0—US Provisional Patent Application
No. 61/865,845 filed 06 November 2013;
‘‘ALK Specific Chimeric Antigen
Receptors,’’ Orentas R, Mackall C.
Licensing Contact: David A.
Lambertson, Ph.D.; 301–435–4632;
lambertsond@mail.nih.gov.
Collaborative Research Opportunity:
The Pediatric Oncology Branch, CCR,
NCI, is seeking statements of capability
or interest from parties interested in
collaborative research to further
develop, evaluate or commercialize
chimeric antigen receptors (CARs)
specific for tumor-expressed CD276
(B7–H3). For collaboration
opportunities, please contact John D.
Hewes, Ph.D. at hewesj@mail.nih.gov.
Competitive Advantages:
• Immunotherapy targets latently
infected cells harboring virus resistant
to HAART.
• Broadly neutralizing antibody
fragment neutralizes extraneous viral
particles.
Development Stage:
• Pre-clinical.
• In vivo data available (animal).
Inventors: Gary J. Nabel, Xiaoti Guo,
Amarenda Pegu, Zhi-yong Yang (all of
NIAID).
Intellectual Property:
• HHS Reference No. E–071–2012/
0—US Application No. 61/638,437 filed
25 April 2012.
• HHS Reference No. E–071–2012/
1—PCT Application No. PCT/US2013/
038214 filed 25 April 2013, which
published as WO 2013/163427 on 31
October 2013.
Licensing Contact: Cristina
Thalhammer-Reyero, Ph.D., M.B.A.;
301–435–4507; ThalhamC@
mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases, Vaccine Research
Center, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize HIV–1 bispecific
antibodies. For collaboration
opportunities, please contact Barry
Buchbinder, Ph.D. at 301–594–1696.
Dated: January 2, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2014–00123 Filed 1–8–14; 8:45 am]
PMANGRUM on DSK3VPTVN1PROD with NOTICES
Bispecific Antibodies To Target Latent
HIV–1 Infection
BILLING CODE 4140–01–P
Description of Technology: The
invention describes bispecific
antibodies designed to kill latently HIV–
1 infected T cells. It is thought that such
bispecific antibodies will reduce or
eliminate the pool of HIV–1 infected
cells, contributing to functional cure.
The antibody constructs comprise an
HIV Env-binding fragment of a broadly
neutralizing antibody linked to an antiCD3 single chain variable fragment
(scFv). One embodiment is a VRC01
scFv linked to the anti-CD3 scFv . Other
embodiments comprise Fab fragments of
VRC07 or 10E8 antibodies linked to the
anti-CD3 scFv. The bispecific antibody
simultaneously stimulates infected cells
to express gp120, instructs cytotoxic T
cells to kill these cells, and neutralizes
extraneous viral particles.
Potential Commercial Applications:
Immunotherapy of HAART-suppressed
HIV–1 infection.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
VerDate Mar<15>2010
14:08 Jan 08, 2014
Jkt 232001
National Institutes of Health
National Institute of Arthritis and
Musculoskeletal and Skin Diseases:
Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Arthritis and Musculoskeletal
and Skin Diseases Advisory Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Arthritis and
Musculoskeletal and Skin Diseases Advisory
Council.
Date: February 11, 2014.
Open: 8:30 a.m. to 12:30 p.m.
Agenda: Discussion of Program Policies.
Place: National Institutes of Health,
Building 31, Room 6, 31 Center Drive,
Bethesda, MD 20892.
Closed: 1:30 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, Room 6, 31 Center Drive,
Bethesda, MD 20892.
Contact Person: Laura K. Moen, Ph.D.,
Director, Division of Extramural Research
Activities, NIAMS/NIH, 6700 Democracy
Boulevard, Suite 800, Bethesda, MD 20892,
301–451–6515 moenl@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.846, Arthritis,
Musculoskeletal and Skin Diseases Research,
National Institutes of Health, HHS).
Dated: January 2, 2014.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–00125 Filed 1–8–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
E:\FR\FM\09JAN1.SGM
09JAN1
]]>Agencies
[Federal Register Volume 79, Number 6 (Thursday, January 9, 2014)]
[Notices]
[Pages 1647-1648]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-00123]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
New Compounds for Treating or Preventing Obesity
Description of Technology: Available for licensing are new
compounds developed for the treatment or prevention of obesity. The
compounds act to block the absorption of dietary fats in the gut by
interfering with signaling through the farnesoid X receptor. There is
correlative evidence that inhibition of the farnesoid X receptor can
reduce obesity resulting from high fat-based diets. While many
farnesoid X receptor agonists are known, until now there have been no
known therapeutic agents that can inhibit this receptor.
Also available for licensing are methods of synthesizing the
compounds and methods of using the compounds to treat or prevent
obesity.
Potential Commercial Applications:
Pharmaceutical treatments for obesity.
Pharmaceutical agents to reduce weight gain.
Competitive Advantages:
There are no known therapeutic agents to inhibit the
farnesoid X receptor; thus, agents developed from the present
technology could be first-to-market.
Compounds stay in the intestine and are not toxic.
Development Stage:
Early-stage.
In vitro data available.
In vivo data available (animal).
Inventors: Frank Gonzalez, Fei Li, Changtao Jiang, James Mitchell
(all of NCI).
Intellectual Property: HHS Reference No. E-508-2013/0--US
Provisional Application No. 61/861,109 filed 01 August 2013.
Licensing Contact: Patrick McCue, Ph.D.; 301-435-5560;
mccuepat@mail.nih.gov.
Chimeric Antigen Receptors to CD276 (B7-H3) for Treatment of Cancer
Description of Technology: Chimeric antigen receptors (CARs) are
hybrid proteins consisting of an antibody binding fragment fused to
protein signaling domains. When CARs are expressed in T-cells, the T-
cells become cytotoxic towards cells expressing the proteins that the
CAR recognizes. By developing a CAR that is specific for a cell surface
protein that is selectively expressed on diseased cells, it is possible
to selectively target those cells for destruction, thereby treating the
disease.
Solid tumors are typically treated with a non-specific approach of
surgical resection, followed by chemotherapy or radiation therapy.
Unfortunately, such an approach is traumatic for the patient, and leads
to numerous side-effects. This suggests that a more specific approach
to treating solid tumors is needed. CD276 (B7-H3) is a tumor-associated
antigen that is expressed on several solid tumors, making it a
promising therapeutic target. This technology concerns the generation
of three high-affinity CARs (CD276.1, CD276.6 and CD276.17) that target
CD276. These CARs can potentially be used in the treatment of cancers
associated with CD276 expression.
Potential Commercial Applications:
Treatment of diseases associated with increased or
preferential expression of CD276.
Specific diseases include neuroblastoma, Ewing's sarcoma,
[[Page 1648]]
rhabdomyosarcoma, and prostate, ovarian, colorectal, and lung cancers.
Competitive Advantages:
High affinity of the CARs increases the likelihood of
successful targeting.
Targeted therapy decreases non-specific killing of
healthy, essential cells, resulting in fewer non-specific side-effects
and healthier patients.
Development Stage:
Early-stage.
In vitro data available.
Inventors: Rimas J. Orentas, et al. (NCI).
Intellectual Property: HHS Reference No. E-104-2013/0-US-01--US
Provisional Patent Application No. 61/805,001 filed 25 March 2013.
Related Technologies:
HHS Reference No. E-291-2012/0--International Patent
Application No. PCT/US2013/060332 filed 18 September 2013; ``M971
Chimeric Antigen Receptors,'' Orentas R, et al.
HHS Reference No. E-007-2014/0--US Provisional Patent
Application No. 61/865,845 filed 06 November 2013; ``ALK Specific
Chimeric Antigen Receptors,'' Orentas R, Mackall C.
Licensing Contact: David A. Lambertson, Ph.D.; 301-435-4632;
lambertsond@mail.nih.gov.
Collaborative Research Opportunity: The Pediatric Oncology Branch,
CCR, NCI, is seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate or
commercialize chimeric antigen receptors (CARs) specific for tumor-
expressed CD276 (B7-H3). For collaboration opportunities, please
contact John D. Hewes, Ph.D. at hewesj@mail.nih.gov.
Bispecific Antibodies To Target Latent HIV-1 Infection
Description of Technology: The invention describes bispecific
antibodies designed to kill latently HIV-1 infected T cells. It is
thought that such bispecific antibodies will reduce or eliminate the
pool of HIV-1 infected cells, contributing to functional cure. The
antibody constructs comprise an HIV Env-binding fragment of a broadly
neutralizing antibody linked to an anti-CD3 single chain variable
fragment (scFv). One embodiment is a VRC01 scFv linked to the anti-CD3
scFv . Other embodiments comprise Fab fragments of VRC07 or 10E8
antibodies linked to the anti-CD3 scFv. The bispecific antibody
simultaneously stimulates infected cells to express gp120, instructs
cytotoxic T cells to kill these cells, and neutralizes extraneous viral
particles.
Potential Commercial Applications: Immunotherapy of HAART-
suppressed HIV-1 infection.
Competitive Advantages:
Immunotherapy targets latently infected cells harboring
virus resistant to HAART.
Broadly neutralizing antibody fragment neutralizes
extraneous viral particles.
Development Stage:
Pre-clinical.
In vivo data available (animal).
Inventors: Gary J. Nabel, Xiaoti Guo, Amarenda Pegu, Zhi-yong Yang
(all of NIAID).
Intellectual Property:
HHS Reference No. E-071-2012/0--US Application No. 61/
638,437 filed 25 April 2012.
HHS Reference No. E-071-2012/1--PCT Application No. PCT/
US2013/038214 filed 25 April 2013, which published as WO 2013/163427 on
31 October 2013.
Licensing Contact: Cristina Thalhammer-Reyero, Ph.D., M.B.A.; 301-
435-4507; ThalhamC@mail.nih.gov.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases, Vaccine Research Center, is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate or commercialize
HIV-1 bispecific antibodies. For collaboration opportunities, please
contact Barry Buchbinder, Ph.D. at 301-594-1696.
Dated: January 2, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-00123 Filed 1-8-14; 8:45 am]
BILLING CODE 4140-01-P
